KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Accumulated Expenses (2016 - 2025)

Alnylam Pharmaceuticals' Accumulated Expenses history spans 17 years, with the latest figure at $1.1 billion for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 36.1% year-over-year to $1.1 billion; the TTM value through Dec 2025 reached $1.1 billion, up 36.1%, while the annual FY2025 figure was $1.1 billion, 36.1% up from the prior year.
  • Accumulated Expenses reached $1.1 billion in Q4 2025 per ALNY's latest filing, down from $1.2 billion in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $1.2 billion in Q3 2025 to a low of $280.5 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $643.8 million, with a median of $648.7 million recorded in 2023.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 61.56% in 2021, then rose 0.76% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $395.2 million in 2021, then skyrocketed by 38.03% to $545.5 million in 2022, then skyrocketed by 30.72% to $713.0 million in 2023, then rose by 11.32% to $793.7 million in 2024, then surged by 36.1% to $1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Accumulated Expenses are $1.1 billion (Q4 2025), $1.2 billion (Q3 2025), and $919.0 million (Q2 2025).